INSM
Price:
$71.04
Market Cap:
$12.21B
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated ...[Read more]
Industry
Biotechnology
IPO Date
2000-06-01
Stock Exchange
NASDAQ
Ticker
INSM
According to Insmed Incorporated’s latest financial reports and current stock price. The company's current Enterprise Value is 12.34B. This represents a change of 100.14% compared to the average of 6.17B of the last 4 quarters.
The mean historical Enterprise Value of Insmed Incorporated over the last ten years is 2.03B. The current 12.34B Enterprise Value has changed 60.81% with respect to the historical average. Over the past ten years (40 quarters), INSM's Enterprise Value was at its highest in in the June 2024 quarter at 10.40B. The Enterprise Value was at its lowest in in the June 2016 quarter at 411.83M.
Average
2.03B
Median
1.84B
Minimum
531.17M
Maximum
5.07B
Discovering the peaks and valleys of Insmed Incorporated Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 146.35%
Maximum Annual Enterprise Value = 5.07B
Minimum Annual Increase = -52.60%
Minimum Annual Enterprise Value = 531.17M
Year | Enterprise Value | Change |
---|---|---|
2023 | 5.07B | 98.03% |
2022 | 2.56B | -13.13% |
2021 | 2.95B | -5.51% |
2020 | 3.12B | 61.82% |
2019 | 1.93B | 132.49% |
2018 | 829.66M | -52.60% |
2017 | 1.75B | 146.35% |
2016 | 710.48M | -11.65% |
2015 | 804.16M | 51.39% |
2014 | 531.17M | 6.14% |
The current Enterprise Value of Insmed Incorporated (INSM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.53B
5-year avg
3.13B
10-year avg
2.03B
Insmed Incorporated’s Enterprise Value is greater than Ascendis Pharma A/S (6.58B), greater than Apellis Pharmaceuticals, Inc. (5.11B), less than BeiGene, Ltd. (19.49B), greater than Akero Therapeutics, Inc. (1.56B), greater than Blueprint Medicines Corporation (6.16B), greater than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Avidity Biosciences, Inc. (4.17B), greater than Revolution Medicines, Inc. (6.80B), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than SpringWorks Therapeutics, Inc. (2.81B), greater than Keros Therapeutics, Inc. (1.58B), greater than Janux Therapeutics, Inc. (2.16B), greater than Fennec Pharmaceuticals Inc. (131.47M), greater than Edgewise Therapeutics, Inc. (1.60B), greater than Harmony Biosciences Holdings, Inc. (1.92B), greater than Halozyme Therapeutics, Inc. (8.85B), greater than Agios Pharmaceuticals, Inc. (2.44B), greater than Ultragenyx Pharmaceutical Inc. (5.53B),
Company | Enterprise Value | Market cap |
---|---|---|
6.58B | $6.83B | |
5.11B | $5.00B | |
19.49B | $21.01B | |
1.56B | $1.83B | |
6.16B | $5.47B | |
8.24B | $8.19B | |
4.17B | $4.74B | |
6.80B | $6.99B | |
1.01B | $1.25B | |
2.81B | $2.88B | |
1.58B | $1.97B | |
2.16B | $2.15B | |
131.47M | $144.76M | |
1.60B | $1.64B | |
1.92B | $2.02B | |
8.85B | $7.50B | |
2.44B | $2.46B | |
5.53B | $5.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insmed Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Insmed Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Insmed Incorporated's Enterprise Value?
What is the highest Enterprise Value for Insmed Incorporated (INSM)?
What is the 3-year average Enterprise Value for Insmed Incorporated (INSM)?
What is the 5-year average Enterprise Value for Insmed Incorporated (INSM)?
How does the current Enterprise Value for Insmed Incorporated (INSM) compare to its historical average?